Comparative Pharmacology
Head-to-head clinical analysis: ANTEPAR versus PRAZIQUANTEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTEPAR versus PRAZIQUANTEL.
ANTEPAR vs PRAZIQUANTEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Praziquantel increases the permeability of schistosome cell membranes to calcium ions, causing severe contraction and paralysis of the worm musculature, leading to dislodgment and death.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
20 mg/kg orally three times daily for 1 day for schistosomiasis; 25 mg/kg orally three times daily for 1 day for clonorchiasis and opisthorchiasis; 5-10 mg/kg orally single dose for taeniasis; 15-25 mg/kg orally single dose for hymenolepiasis; 25 mg/kg orally three times daily for 1 day for paragonimiasis, fasciolopsiasis, and heterophyiasis.
None Documented
None Documented
Clinical Note
moderatePraziquantel + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Praziquantel."
Clinical Note
moderatePraziquantel + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Praziquantel."
Clinical Note
moderatePraziquantel + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Praziquantel."
Clinical Note
moderatePraziquantel + Cyclosporine
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is 1-1.5 hours for praziquantel; 4-6 hours for its main metabolite (4-hydroxypraziquantel). Half-life prolonged in patients with severe hepatic impairment.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Primarily renal: approximately 80% of metabolites excreted in urine (unchanged drug <0.1%); fecal excretion accounts for about 15%.
Category C
Category A/B
Anthelmintic
Anthelmintic
"The metabolism of Cyclosporine can be decreased when combined with Praziquantel."